» Articles » PMID: 10735494

Hevin is Down-regulated in Many Cancers and is a Negative Regulator of Cell Growth and Proliferation

Overview
Journal Br J Cancer
Specialty Oncology
Date 2000 Mar 29
PMID 10735494
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

We have cloned a human Hevin cDNA from omental adipose tissue of different patients by reverse transcription polymerase chain reaction and shown a sequence variation due to a possible polymorphism at amino acid position 161 (E/G). Hevin protein expressed in vitro showed molecular weights of approximately 75 kDa and 150 kDa, suggesting that Hevin may form a homodimer in vitro. Using Northern blots and a human expressed sequence tAg database analysis, Hevin was shown to be widely expressed in human normal or non-neoplastic diseased tissues with various levels. In contrast to this, its expression was strongly down-regulated in most neoplastic cells or tissues tested. However, neither the mechanism nor the physiological meaning of this down-regulation is known. As an initial step towards investigating the functional role of Hevin in cell growth and differentiation, we transiently or stably expressed this gene in cancer cells (HeLa 3S) that are devoid of endogenous Hevin and measured DNA synthesis (cell proliferation) by 5-bromo-2'-deoxyuridine incorporation. Hevin was shown to be a negative regulator of cell proliferation. Furthermore, we have shown that Hevin can inhibit progression of cells from G1 to S phase or prolong G1 phase. This is the first report which describes the function of Hevin in cell growth and proliferation. Through database analysis, Hevin was found to be located on chromosome 4 which contains loss of heterozygosity of many tumour suppressor genes. Taken together, these results suggest that Hevin may be a candidate for a tumour suppressor gene and a potential target for cancer diagnosis/therapy.

Citing Articles

Secretome profiling of extract-loaded polymeric nanoparticle-treated MCF-7 and MDA-MB-231 revealed perturbation in microtubule assembly and cell migration.

Kauser S, Mughees M, Mangangcha I, Swami S, Wajid S Front Oncol. 2023; 13:1209168.

PMID: 37719007 PMC: 10502211. DOI: 10.3389/fonc.2023.1209168.


Sparcl1 and Atherosclerosis.

Cheng X, Chen X, Zhang M, Wan Y, Ge S, Cheng X J Inflamm Res. 2023; 16:2121-2127.

PMID: 37220502 PMC: 10200116. DOI: 10.2147/JIR.S406907.


Association of serum secreted protein acidic and rich in cysteine-like protein 1 with metabolic measures and dyslipidemia among Chinese adults.

Hu C, Wang S, Lin L, Qi H, Lin H, Jia X Front Endocrinol (Lausanne). 2022; 13:1018657.

PMID: 36387870 PMC: 9647160. DOI: 10.3389/fendo.2022.1018657.


Extracellular Vesicle-Derived miR-105-5p Promotes Malignant Phenotypes of Esophageal Squamous Cell Carcinoma by Targeting SPARCL1 FAK/AKT Signaling Pathway.

He B, Zhang K, Han X, Su C, Zhao J, Wang G Front Genet. 2022; 13:819699.

PMID: 35309127 PMC: 8927724. DOI: 10.3389/fgene.2022.819699.


SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.

Zhang H, Wu J, Liu Z, Gao J, Li S Biomed Res Int. 2022; 2022:1398268.

PMID: 35111844 PMC: 8803425. DOI: 10.1155/2022/1398268.


References
1.
Santos J, Herranz M, Perez de Castro I, Pellicer A, Fernandez-Piqueras J . A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4. Oncogene. 1998; 17(7):925-9. DOI: 10.1038/sj.onc.1202009. View

2.
Taylor J, Coutinho L, Herring K, Gallagher Jr D, Brenneman R, Burney N . Candidate gene analysis of GH1 for effects on growth and carcass composition of cattle. Anim Genet. 1998; 29(3):194-201. DOI: 10.1046/j.1365-2052.1998.00317.x. View

3.
Lagadic-Gossmann D, Rissel M, Le Bot M, Guillouzo A . Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture. Cell Biol Toxicol. 1998; 14(5):361-73. DOI: 10.1023/a:1007589808761. View

4.
Vindelov L, Christensen I, Keiding N, Spang-Thomsen M, Nissen N . Long-term storage of samples for flow cytometric DNA analysis. Cytometry. 1983; 3(5):317-22. DOI: 10.1002/cyto.990030502. View

5.
Funk S, Sage E . The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc Natl Acad Sci U S A. 1991; 88(7):2648-52. PMC: 51295. DOI: 10.1073/pnas.88.7.2648. View